Paper Details

  1. Home
  2. Paper Details

Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.

Author: AutioKaren A, BaschEthan, BennettAntonia V, CornPaul G, GeorgeDaniel J, GordonMichael S, HaasNaomi B, HarzstarkAndrea L, HiganoCelestia S, RathkopfDana E, SartorA Oliver, ScheffoldChristian, ScherHoward I, SchimmollerFrauke, SmithDavid C, SmithMatthew R, SweeneyChristopher, VogelzangNicholas J, WeitzmanAaron L, de BonoJohann S

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Cabozantinib demonstrated clinically meaningful pain palliation, reduced or eliminated patients' narcotic use, and improved patient functioning.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Pain negatively affects quality of life for cancer patients. Preliminary data in metastatic castration-resistant prostate cancer (mCRPC) suggested a benefit of the oral tyrosine kinase inhibitor cabozantinib to pain palliation. OBJECTIVE: Prospective evaluation of cabozantinib's benefit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eururo.2014.02.013

データ提供：米国国立医学図書館（NLM）

Cabozantinib for Pain Management in Castration-Resistant Prostate Cancer

The battle against prostate cancer is a relentless desert trek. This study examines the potential of cabozantinib, an oral tyrosine kinase inhibitor, for pain management in patients with metastatic castration-resistant prostate cancer (mCRPC). Researchers analyzed data from 144 patients to determine the effectiveness of cabozantinib in reducing pain and narcotic use.

Cabozantinib Shows Promise in Pain Palliation

The study found that cabozantinib demonstrated clinically meaningful pain reduction in a significant number of patients with moderate or severe baseline pain. This encouraging result suggests that cabozantinib may offer valuable relief for patients suffering from the debilitating pain associated with mCRPC.

A Beacon of Hope in the Desert of Pain

This study provides a beacon of hope in the desert of pain experienced by mCRPC patients. While further studies are necessary to confirm these findings, cabozantinib holds promise as a potential pain management tool. It underscores the importance of exploring new approaches to combatting pain and improving the quality of life for cancer patients.

Dr.Camel's Conclusion

This study offers a glimmer of hope in the desert of mCRPC pain. Cabozantinib emerges as a potential oasis, providing relief from the relentless suffering associated with this disease. As we continue to explore this complex landscape, we can strive to alleviate pain and improve the lives of patients battling this formidable foe. Remember, in the face of adversity, we must never lose sight of our goal: to provide comfort and support to those who need it most.
Date :
  1. Date Completed 2015-12-17
  2. Date Revised 2021-03-10
Further Info :

Pubmed ID

24631409

DOI: Digital Object Identifier

10.1016/j.eururo.2014.02.013

Related Literature

Article Analysis
・Effects of cabozantinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.